ABSTRACT. The pharmacokinetic characteristics of testosterone propionate were studied in normal men after a single im
T ESTOSTERONE propionate is a short-acting parenteral form of testosterone used primarily in the treatment of hypogonadism, oligospermia, and impotence (1) . Although the clinical use of testosterone propionate has been investigated, pharmacokinetic studies have been limited by the lack of a specific and sensitive assay. Testosterone propionate in pharmaceutical preparations has been measured by gas chromatography (GC) (2, 3) , high performance liquid chromatography (4), high performance thin layer chromatography (5) , infrared spectrophotometry (6) , and colorimetry (7) . Howevern one of these methods allowed measurement of testosterone propionate in biological fluids, because of low sensitivity and low selectivity. In attempts to examine the disposition of testosterone propionate, RIA (8) (9) (10) and competitive protein binding assay (11, 12) have been used to detect changes in unesterified testosterone concentrations in plasma after im administration of testosterone propionate. However, no direct evidence is available regarding the pharmacokinetics of im administered testosterone propionate. RIA and competitive protein binding assay cannot address this problem, since this type of assay cannot differentiate between endogenous testosterone and testosterone derived from administered testosterone propionate.
We have initiated studies designed to characterize the pharmacokinetic properties of im administered testos-terone propionate and to determine the effect of testosterone propionate on endogenous testosterone levels. We reported previously the determination of plasma testosterone propionate levels by GC-mass spectrometry-selected ion monitoring (GC-MS-SIM) (13) . The present paper describes the applications of GC-MS techniques for the pharmacokinetic study of deuterated testosterone propionate after the im administration of testosterone propionate-19,19,19-d 3 tO normal men.
Materials and Methods

Chemicals
Testosterone propibnate -19,19i,19-d3 (testosterone propionate-19-d 3 ) and testosterone-i9,l9,19-d 3 (testosterone-l9-d 3 ) were synthesized in our laboratory, as described previously (13, 14) . Their isotoplc compositions were 99.0% deuterium atoms (da, 97.8%; d 2 , 2.2%; d lt 0.0%). Unlabeled testosterone propionate (Tokyo Chemical Industry, Tokyo, Japan) and trifluoro.acetic anhydride (Nakarai Chemicals Ltd., Kyoto, Japan) were obtained commercially. The testosterone propionate-19-d3 preparation for im injection was prepared by dissolving 25 mg testosterone propionate-19-0*3 in 1 ml sesame oil containing 20% benzyl benzoate, followed by membrane filtration to insure sterility.
GC-MS-SIM
GC-MS-SIM measurements were made in the El-mode with a Shimadzu LKB-9000B gas chromatbgraph-mass spectrometer equipped with Shimadzu high speed multiple ion detectorpeak matcher 9060S. The GC column was a glass column (id,
Vol 63 • No 6 2 rri x 3 mm) packed with 1.5% OV-1 on Shimalate W (80-100 mesh). The injector, column, and ion source temperatures were 260, 230, and 270 C, respectively. Helium was used as the carrier gas at a flow rate of 30 ml/min. The electron energy was set at 20 eV, and the trap current at 60 nA. The multiple ion detector was focused at the molecular ions of the trifluoroacetate derivatives of testosterone propionate (do, m/z 440; d 3 , m/z 443) and testosterone (do, m/z 480; d 3 , m/z 483) to obtain peak height ratios.
Testosterone propionate-19-d 3 administration studies
The study subjects were two normal men, 27 and 24 yr old, weighing 72 and 61 kg, respectively. To determine the secretory dynamics of endogenous testosterone, heparinized blood samples (10 ml) were obtained at 0800 ; 1100, 1400,1700, and 2000 h for 4 days. The men then were given 25 mg testosterone propionate-19-d3, im, at 0800 h. Ten-milliliter heparinized blood samples were obtained 5 min before and 3, 6, 9, 12, 24, 27, 30, 33, 36, 48, 54, 60, 72, 78, and 84 h after dosing. Plasma was separated by centrifugation and stored at -20 C until analysis.
Sample preparation for GC-MS-SIM
To measure the secretory dynamics of endogenous testosterone, plasma samples were subjected to GC-MS-SIM analysis, as described previously (15) . Briefly, 10 ng testosterone-19-dg were added as an internal standard to 1.0 ml plasma, and the plasma sample was extracted with ether. The ether extract was cooled to -15 G and centrifuged to remove plasma lipids. After purification of the ether extract by thin layer chromatography and derivatization with trifluoroacetic anhydride, 1-3 nl sample dissolved in 20 /x\ n-hexane were analyzed by GC-MS-SIM. This assay has a sensitivity of O.i ng/ml plasma and an interassay coefficient of variation of 3.6% (5.9 ng/ml plasma) based on measurement of three samples in triplicate.
To measure testosterone propionate-19-d3 in plasma, plasma samples were subjected to the GC-MS-SIM analytic method described previously (13) . Briefly, 20 ng unlabeled testosterone propionate were added as an internal standard to 1.0 ml plasma. To avoid hydrolysis of testosterone propionate during the extraction procedure and the presence of numerous interfering peaks at m/z 440 and 443, the plasma sample was cooled to 4 C and extracted with n-hexane. The h-hexane extract was cooled to -15 C and centrifuged to remove plasma lipids. After derivatization with trifluoroacetic anhydride, 1-3 /xl sample dissolved in 20 n\ n-hexane were analyzed by GC-MS-SIM. This assay has a sensitivity of 0.2 ng/ml plasma and an interassay coefficient of variation of 3.5% (2.6 ng/ml plasma) based on measurement of three samples in triplicate.
The double isotope dilution method was employed to measure testosterone-19-d3 and endogenous testosterone in plasma simultaneously. Plasma samples (1.0 ml each) were divided into two aliquots each. To one aliquot of each sample was added testosterone-19-d3 (10 ng) as an internal standard. The two aliquots of plasma were cooled to 4 C and then subjected to GC-MS-SIM analysis, as described previously (15) . The calculations used to determine testosterone-19-d3 and endogenous testosterone levels, as assayed by the double isotope dilution method, were described previously (16) .
Data analysis
Independent modeling techniques, described by Yamaoka et al. (17) and Riegelman and Collier (18) , were used to calculate the pharmacokinetic parameters of testosterone propionate-19-d3 and testosterone-19-d3. The estimation of the elimination half-life (ti /2 ) was obtained from at least five points of the terminal log-linear portion of the curve. The area under the plasma concentration time curve (AUC) was calculated by the trapezoidal method. The area under the first moment of the curve (AUMC) was computed similarly by multiplying each individual plasma concentration by its time. Extrapolations through infinity were calculated from the last detectable plasma concentration and the terminal elimination half-life. The systemic plasma clearance (CL 8 ), the mean residence time (MRT), and the steady state volume of distribution (V S8 ) were determined with Eq I-III (19) . 
Results
Endogenous plasma testosterone profiles
Before studying the disposition of testosterone propionate, we determined the levels of endogenous plasma testosterone for 4 days in the two normal men (Fig. 1) . The mean plasma testosterone concentration in subject 1 was 6.6 ng/ml, with a range of 4.0-8.9 ng/ml. Subject 2 had a mean value of 6.9 ng/ml and a range of 4.7-9.3 ng/ml. Testosterone concentrations had a circadian rhythm, with the highest levels between 0800 and 1100 TESTOSTERONE PROPIONATE KINETICS 1363 h and the lowest levels between 1700 and 2000 h in both men.
Plasma testosterone propionate-19-d 3 and testosterone-19-da concentrations
Plasma testosterone propioriate-19-d 3 levels were maintained at 2-4 ng/ml between 3 and 36 h after im administration of a single 25-mg dose of testosterone propionate-19-d 3 (Fig. 2) and thereafter decreased very slowly. Testosterone-19-d 3 was detected in the first blood sample taken 3 h after the injection. The maximum plasma testosterone-19-d 3 levels (15.0 ng/ml for subject 1 and 11.5 ng/ml for subject 2) occurred between 24 and 27 h. Thereafter, the decline of testosterone-19-d 3 was parallel to that of testosterone propionate-19-d 3 in both subjects. The pharmacokinetic parameters characterizing the disposition of testosterone propionate-19-d 3 and testosterone-19-d 3 are summarized in Table 1 .
Effect of testosterone propionate-19-d^ on plasma endogenous testosterone
Endogenous plasma testosterone levels were measured at various times for 84 h after the im testosterone propionate-19-d 3 injection. The results are shown in Fig. 2 . Endogenous testosterone levels just before the administration of testosterone prOpionate-19-d 3 were 7.2 ng/ml in subject 1 and 7.5 ng/ml in subject 2. After the administration of testosterone propionate-19-d 3 , endogenous testosterone levels varied between 3.8 and 7.8 ng/ml and 4.4 and 7.5 ng/ml in subjects 1 and 2, respectively.
Discussion
The use of GC-MS and stable isbtopically labeled drugs as tracers makes it possible to provide a precise analytical method for both the parent compound and metabolites with high sensitivity and selectivity (20) (21) (22) . The application of this method allowed us to follow the plasma levels of testosterone propionate-19-d 3 and its active metabolite testosterone-19-d3 for 84 h after the im administration of testosterone propionate-19-d 3 .
Intramuscularly administered testosterone propionate-19-d 3 was readily detected in the circulation, demonstrating clearly that the testosterone propionate-19-d3 was transferred from the injection site in the muscle to the systemic circulation.
Nieschlag et al. (8) measured the total plasma exogenous and endogenous testosterone levels by RIA after the im administration of 25 mg testosterone propionate to normal men. Total plasma testosterone levels were maintained above the physiological levels for 24 h after drug administration. However, it was not possible to determine exactly the contribution of administered testosterone propionate to the total concentration of circulating testosterone. With the aid of the double isotope dilution assay employed in this study, endogenous testosterone and testosterone derived from administered testosterone propionate could be differentiated easily. Conversion of testosterone propionate-19-d 3 to testosterone-19-d 3 was fast in the systemic circulation, and testosterone propionate-19-d 3 injection resulted in exogenous testosterone levels above the normal testosterone level (>4 ng/ml) for 48 h. Moreover, exogenous testosterone continued to contribute to the total plasma levels for up to 84 h.
Significant decreases in plasma LH occur after the im administration of testosterone preparations to normal men (8, 12, (23) (24) (25) . This decrease is caused by the negative feedback effect of exogenous testosterone on LH secretion, which, in turn, should result in suppression of testicular secretion of testosterone. However, no direct evidence concerning the effect of exogenous testosterone on endogenous testosterone levels is yet available. In our study, administration of testosterone pfopionate-19-d3 was followed by a gradual decline in plasma endogenous testosterone levels, which then returned to pretreatment levels 24 h after the administration of testosterone propionate-19-d 3 . However, the circadian testosterone rhythm, as documented in these men before testosterone propionate administration, could have resulted in the curves obtained after testosterone propionate administration. Thus, we cannot conclude that endogenous testosterone production was suppressed by the single dose of testosterone propionate administered.
